BridgeBio Oncology Therapeutics (BBOT) announced promising preliminary clinical results for its three RAS-pathway inhibitor programs targeting KRAS mutations in cancers, showing encouraging anti-tumor activity and safety profiles. Key drugs BBO-8520, BBO-11818, and BBO-10203 demonstrated efficacy in lung, pancreatic, colorectal, and breast cancers with ongoing trials and combination studies planned. BBOT also reported a solid cash position of $388.9 million, expected to fund operations through 2028, supporting continued development and upcoming clinical data readouts in the second half of 2026. These advances position BBOT to potentially offer new treatment options for patients with cancers driven by RAS mutations.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
